Moderna (MRNA) Stock Price, News & Analysis

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Moderna in the last year. There are currently 2 sell ratings, 8 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MRNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRNA, but not buy additional shares or sell existing shares.
View MRNA analyst ratings or view top-rated stocks.

16 analysts have issued 12-month target prices for Moderna's stock. Their MRNA share price targets range from $60.00 to $231.00. On average, they predict the company's share price to reach $126.89 in the next twelve months. This suggests a possible upside of 7.8% from the stock's current price.
View analysts price targets for MRNA or view top-rated stocks among Wall Street analysts.

Moderna's stock was trading at $99.45 on January 1st, 2024. Since then, MRNA shares have increased by 18.4% and is now trading at $117.75.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our MRNA earnings forecast.

Moderna, Inc. (NASDAQ:MRNA) released its earnings results on Thursday, May, 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.59) by $0.52. The business had revenue of $167 million for the quarter, compared to analysts' expectations of $93.26 million. Moderna had a negative net margin of 115.82% and a negative trailing twelve-month return on equity of 20.10%. The business's quarterly revenue was down 91.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.19 earnings per share.

ETFs with the largest weight of Moderna (NASDAQ:MRNA) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM), VanEck Biotech ETF (BBH), Morningstar US Small Growth (MSGR), iShares Genomics Immunology and Healthcare ETF (IDNA), Invesco Nasdaq Biotechnology ETF (IBBQ), Global X Genomics & Biotechnology ETF (GNOM), iShares Biotechnology ETF (IBB) and First Trust NYSE Arca Biotechnology Index Fund (FBT).

Moderna issued an update on its FY 2024 earnings guidance on Friday, May, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $4.0 billion-$4.0 billion, compared to the consensus revenue estimate of $3.9 billion.

57 employees have rated Moderna Chief Executive Officer Stéphane Bancel on Glassdoor.com. Stéphane Bancel has an approval rating of 92% among the company's employees. This puts Stéphane Bancel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Moderna investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Pfizer (PFE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Johnson & Johnson (JNJ), Alibaba Group (BABA) and Zoom Video Communications (ZM).

Moderna (MRNA) raised $499 million in an initial public offering on Friday, December 7th 2018. The company issued 21,700,000 shares at a price of $22.00-$24.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers.

Moderna's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (11.66%), Bank of New York Mellon Corp (0.60%), Mawer Investment Management Ltd. (0.50%), Sumitomo Mitsui Trust Holdings Inc. (0.40%), Swiss National Bank (0.25%) and Mitsubishi UFJ Trust & Banking Corp (0.20%). Insiders that own company stock include Arpa Garay, David W Meline, Dustin A Moskovitz, James M Mock, Juan Andres, Lori M Henderson, Lori M Henderson, Noubar Afeyan, Paul Sagan, Shannon Thyme Klinger, Stephane Bancel, Stephen Hoge, Tal Zvi Zaks and W Don Cornwell.
View institutional ownership trends.

Shares of MRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.